Solid Organ Transplantation and the Use of Raltegravir in HIV-Infected Patients: An Observational Study of Pharmacokinetics, Safety, Tolerability and Efficacy
Latest Information Update: 12 May 2022
Price :
$35 *
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Pharmacodynamics
- 14 Aug 2017 Status changed from recruiting to completed.
- 22 Jul 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2017.
- 22 Feb 2013 New trial record